Copyright Reports & Markets. All rights reserved.

Global Kidney Fibrosis Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Kidney Fibrosis Treatment Industry
  • 1.7 COVID-19 Impact: Kidney Fibrosis Treatment Market Trends

    • 2 Global Kidney Fibrosis Treatment Quarterly Market Size Analysis

    • 2.1 Kidney Fibrosis Treatment Business Impact Assessment - COVID-19
      • 2.1.1 Global Kidney Fibrosis Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Kidney Fibrosis Treatment Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Kidney Fibrosis Treatment Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Kidney Fibrosis Treatment Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Kidney Fibrosis Treatment Market
    • 3.4 Key Players Kidney Fibrosis Treatment Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Kidney Fibrosis Treatment Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Angiotensin Converting Enzyme (ACE) Inhibitors
      • 1.4.2 Pirfenidone
      • 1.4.3 Renin Inhibitors
      • 1.4.4 Angiotensin II Receptor Blockers (ARBs)
      • 1.4.5 Vasopeptidase Inhibitors
    • 4.2 By Type, Global Kidney Fibrosis Treatment Market Size, 2019-2021

    5 Impact of Covid-19 on Kidney Fibrosis Treatment Segments, By Application

    • 5.1 Overview
      • 5.5.1 Chronic Kidney Diseases
      • 5.5.2 Kidney Cancer Treatment
      • 5.5.3 Others
    • 5.2 By Application, Global Kidney Fibrosis Treatment Market Size, 2019-2021
      • 5.2.1 By Application, Global Kidney Fibrosis Treatment Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Merck and Co(US)
      • 7.1.1 Merck and Co(US) Business Overview
      • 7.1.2 Merck and Co(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.1.3 Merck and Co(US) Kidney Fibrosis Treatment Product Introduction
      • 7.1.4 Merck and Co(US) Response to COVID-19 and Related Developments
    • 7.2 Pfizer Inc(US)
      • 7.2.1 Pfizer Inc(US) Business Overview
      • 7.2.2 Pfizer Inc(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Product Introduction
      • 7.2.4 Pfizer Inc(US) Response to COVID-19 and Related Developments
    • 7.3 F. Hoffman-La Roche(Switzerland)
      • 7.3.1 F. Hoffman-La Roche(Switzerland) Business Overview
      • 7.3.2 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Product Introduction
      • 7.3.4 F. Hoffman-La Roche(Switzerland) Response to COVID-19 and Related Developments
    • 7.4 InterMune Inc(US)
      • 7.4.1 InterMune Inc(US) Business Overview
      • 7.4.2 InterMune Inc(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Product Introduction
      • 7.4.4 InterMune Inc(US) Response to COVID-19 and Related Developments
    • 7.5 Galectin Therapeutics(US)
      • 7.5.1 Galectin Therapeutics(US) Business Overview
      • 7.5.2 Galectin Therapeutics(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Product Introduction
      • 7.5.4 Galectin Therapeutics(US) Response to COVID-19 and Related Developments
    • 7.6 La Jolla Pharmaceutical Company(US)
      • 7.6.1 La Jolla Pharmaceutical Company(US) Business Overview
      • 7.6.2 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Product Introduction
      • 7.6.4 La Jolla Pharmaceutical Company(US) Response to COVID-19 and Related Developments
    • 7.7 ProMetic Life-Sciences Inc(Canada)
      • 7.7.1 ProMetic Life-Sciences Inc(Canada) Business Overview
      • 7.7.2 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Product Introduction
      • 7.7.4 ProMetic Life-Sciences Inc(Canada) Response to COVID-19 and Related Developments
    • 7.8 BioLine Rx(Israel)
      • 7.8.1 BioLine Rx(Israel) Business Overview
      • 7.8.2 BioLine Rx(Israel) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Product Introduction
      • 7.8.4 BioLine Rx(Israel) Response to COVID-19 and Related Developments
    • 7.9 Genzyme Corporation(US)
      • 7.9.1 Genzyme Corporation(US) Business Overview
      • 7.9.2 Genzyme Corporation(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
      • 7.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Product Introduction
      • 7.9.4 Genzyme Corporation(US) Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Kidney Fibrosis Treatment, including the following market information:
      Global Kidney Fibrosis Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Kidney Fibrosis Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Kidney Fibrosis Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Kidney Fibrosis Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland), InterMune Inc(US), Galectin Therapeutics(US), La Jolla Pharmaceutical Company(US), ProMetic Life-Sciences Inc(Canada), BioLine Rx(Israel), Genzyme Corporation(US), etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Angiotensin Converting Enzyme (ACE) Inhibitors
      Pirfenidone
      Renin Inhibitors
      Angiotensin II Receptor Blockers (ARBs)
      Vasopeptidase Inhibitors

      Based on the Application:
      Chronic Kidney Diseases
      Kidney Cancer Treatment
      Others

      Buy now